Home | RheumNow

Recent News

Mixed Drinks, Mixed Results (10.30.2026)
Save

Jack Cush, MD

Oct 30, 2026

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.

Read Article

Menopause Hormone Therapy Tied to Small Autoimmune Disease Risk Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested. https://t.co/kV4Y7tvpC8

Rituximab or Azathioprine for EGPA Maintenance? A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone. https://t.co/UrHqPBVibn https://t.co/cpusNcpYWd

Rituximab or Azathioprine for EGPA Maintenance? | RheumNow

Grappa Symposium: Leung Obesity in PsA - done deal @RheumNow #APLAR2026 https://t.co/3YQT4kiPer

AxSpA+rash vs Axial PsA Kishimoto : two phenotypes of the same disease and to maximise specificity Axis study - imaging criteria = AxSpA phenotype @RheumNow #APLAR2026 https://t.co/UYFnA3AyUM

https://x.com/drpnash/status/2116402903040897383/photo/1

An important and relevant reminder from @rheumarhyme on AI use @RheumNow #APLAR2026 https://t.co/7Ratb6aQOD

https://x.com/RHEUMarampa/status/2116369684358684894/photo/1

AI can be helpful in manuscript creation As the author: > always verify the draft - allow time to check > take full responsibility of the content - review and revise the final manuscript @RheumNow #APLAR2026 https://t.co/cQsEtDc7z1

Case quiz: 38F fever, tetraparesis, hallucinations, slurred speech. Low C3, ANA 1:100, WBC 26,320, normal CSF/Ca/PTH. CT: basal ganglia calcification. Dx? Answer: SLE with Fahr syndrome (focal NPSLE) plus urosepsis. Keep infection in rheum Ddx. P#325 #APLAR26 @RheumNow https://t.co/Gsb8dquwHL

https://x.com/JihaRheum/status/2116329865196552649/photo/1

Dr. Poddubny on AI & machine learning in SpA AI has enabled the analysis of large data sets offering a support for clinical decision-making. Future directions? Making scans faster leading to rapid analysis Challenge: access to large, high quality data @RheumNow #APLAR2026 https://t.co/UhdjSRXtOv

Better drugs only help if patients can get them. In an APLAR PsA registry, 43% of lowest-GDP patients had not reached MDA and were not on a biologic or targeted DMARD. Coverage, reimbursement and social support needed, not just science. P#242 #APLAR26 @RheumNow https://t.co/Rms4QsbcII

https://x.com/JihaRheum/status/2116327499210842589/photo/1

Raychaudhuri (day 2 plenary): Reconceptualizing cells as continuous states, not discrete types. In RA synovium, AMP defined six inflammation patterns (CTAPs) with key cell states, e.g. Tph in T+B. Do CTAPs respond to different targets? #APLAR26 @RheumNow https://t.co/jIosTqv5qZ

FDA has approved the IL-23 inhibitor tildrakizumab (Ilumya) use in adults with active psoriatic arthritis (PsA), expanding the interleukin indications beyond moderate-to-severe plaque psoriasis. (Based on INSPIRE-1/2; >800 adults, 52-week RCTs) https://t.co/tCKZQwf74A https://t.co/Qffr1ZAMd7

FDA Approves Tildrakizumab for Psoriatic Arthritis in Adults

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? The treatment of active TAK is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage. https://t.co/J1EQHGzR5O https://t.co/i59kRGJCoK

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? | RheumNow

Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 https://t.co/JCTszYa57m

Novartis receives European Commission approval for Cosentyx® in polymyalgia rhe…

JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/xTlr5lrwUz

"We really need to ask every patient who has psoriasis about their joints” – Dr. Ahmad Amin, Dermatologist Watch Dr. Amin and Dr. Saakshi Khattri discuss the link between skin and joints in PsA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/rp2e5oknVF https://t.co/nf2vpvNJuV

PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives | RheumNow

Prof. Mease shares this important slide illustrating how excessive adipose tissue contributes to PsA dev’t 👇 Dysfunctional adipose tissue enables overall amplification of inflammation in obese pts with PsA @RheumNow #APLAR2026 https://t.co/1YtcqxM4B3

https://x.com/RHEUMarampa/status/2116085070146801824/photo/1

Optimizing GC use in SLE: In arthritis, avoid oral GC - consider NSAIDS, csDMARDs, small molecules or biologics On GC initiation, hit hard w/pulse MP then taper early and rapidly In LN, treat aggressively bec damage is driven by dse activity, not meds @RheumNow #APLAR2026 https://t.co/Q5gFpr8P9k

OA injections span three tiers: symptom-modifying (steroid, HA, polynucleotides), structure-oriented (sprifermin, Wnt inhibitors) and biologic (PRP, MSCs, EVs). None looks far superior to steroid or HA for symptoms; structural benefit is the goal. OA SIG #APLAR26 @RheumNow https://t.co/4R6Oxd0BvL

The @RheumNow crew together at #APLAR2026 https://t.co/9YizHIFprF

https://x.com/JihaRheum/status/2116043911718441344/photo/1

Video

Podcasts

DERM on RheumNow PODCAST (October 2026)
Oct 31, 2026
Mixed Drinks, Mixed Results (10.30.2026)
Oct 30, 2026
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
Oct 28, 2026
Double Trouble (10.23.2026)
Oct 23, 2026

Submit your Rheumatology question or case here

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Sponsored by AbbVie Medical Affairs + Health Impact

Nov 01, 2026

In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions

Read Post